Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus OXTRIPHYLLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus OXTRIPHYLLINE.
DILOR-400 vs OXTRIPHYLLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Clinical Note
moderateOxtriphylline + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Acemetacin
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Clotrimazole
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Renal (70% unchanged), hepatic metabolism (30%)
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Clotrimazole can be decreased when combined with Oxtriphylline."